IQVIA (IQV) Scheduled to Post Quarterly Earnings on Thursday

IQVIA (NYSE:IQV) is scheduled to release its earnings data before the market opens on Thursday, May 2nd. Analysts expect IQVIA to post earnings of $2.19 per share for the quarter. IQVIA has set its FY24 guidance at $10.95-11.25 EPS and its FY 2024 guidance at 10.950-11.250 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

IQVIA (NYSE:IQV) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.02. The firm had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The company’s revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the company earned $2.54 earnings per share. On average, analysts expect IQVIA to post $10 EPS for the current fiscal year and $12 EPS for the next fiscal year.

IQVIA Stock Up 0.3 %

IQV opened at $235.48 on Tuesday. IQVIA has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a market cap of $42.74 billion, a PE ratio of 32.30, a price-to-earnings-growth ratio of 2.27 and a beta of 1.50. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. The company has a 50 day moving average of $245.21 and a 200 day moving average of $223.56.

Insider Buying and Selling at IQVIA

In other news, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the transaction, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The disclosure for this sale can be found here. Insiders sold 41,285 shares of company stock valued at $10,331,003 in the last quarter. Company insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Evercore ISI raised their price objective on shares of IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a research report on Thursday, February 15th. Leerink Partnrs reaffirmed an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Finally, Robert W. Baird raised their price target on IQVIA from $226.00 to $251.00 and gave the company a “neutral” rating in a research report on Thursday, February 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $256.80.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.